Medical Therapeutics

Vedere

Brief Description

Vedere Bio, Inc. was developing gene therapy products to restore functional vision to patients who have suffered vision loss from inherited retinal degenerations, as well as other causes of both genetic and non-genetic vision loss. Vedere aimed to restore lost vision regardless of a patient's underlying genetics or their stage of disease.

Vedere was acquired by Novartis in 2020.

Timeline 2019. Company founded 2020. Vedere acquired by Novartis Inventors

Ehud Isaacoff, John Flannery, Amy Holt, Autoosa Salari, Benjamin Gaub,...

Valitor Inc.

Brief Description

Valitor, Inc. has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacokinetics, target specificity, and bioactivity. The company's technology platform can be broadly applied to improve the pharmacological properties of many protein drugs that are currently approved or under development. The lead product will be used to improve the treatment of diseases in ophthalmology. The company also has development pipelines for oncology and orthopedics products.

The company was incubated at Berkeley Skydeck, UC Berkeley's...

Tularik Inc.

Brief Description

Tularik, Inc. engages in the discovery and development of orally available medicines that act through the regulation of gene expression. The company’s drugs include T67, T607, T131, T71, and T487. The T67 is an anti-cancer drug. The T607 would be used for treating gastric cancer and esophageal cancer. The T131 would be used for treating diabetes. The T71 would be used for treating obesity.

Tularik Inc. was acquired by Amgen Inc. for approximately $1.3 billion in 2004.

Timeline 1991. Company founded 1999. Initial public offering...

Tilden Bio

Brief Description

Development of photosynthetic bioproducts including natural plant essential oils, cannabinoids, and biopharmaceutical proteins. The technology has been applied to enhance yields of high-value photosynthetic bioproducts in the UC Berkeley Melis Laboratory.

Formerly known as Tabletop Energy.

Timeline 2019. Company incorporated Inventors

Nico Betterle, Fiona Davies, Cinzia Formighieri, Diego Hidalgo Martinez, Henning Kirst, Andrew Saphire, Hsu Ching Wintz, Andreas Zurbriggen, Anastasios Melis

Thuris Corporation

Brief Description

Thuris Corporation was a biopharmaceutical company focused on medical device solutions to aid in drug development and diagnosis of central nervous system (CNS) disorders including mild cognitive impairment and Alzheimer's disease. Thuris was also developing pharmaceuticals for select CNS orphan and niche indications ranging from ischemia-related conditions, brain inflammation and Huntington's disease. Thuris received 510k FDA clearance for a non-invasive medical device, the NeuroGraph, for diagnosis of neurological and psychiatric disorders over a broad range of brain-...

Synvivia, Inc.

Brief Description

Synvivia is a synthetic biology company that optimizes cell behavior for gene therapy manufacturing, providing a practical solution for genetically encoded biocontainment. The company is building genetically encoded biocontainment technologies that will enable the widespread use of synthetic biology outside of the laboratory.

The company's technology was developed at UC Berkeley with grants from the NSF and DARPA. The work was published in ACS Synthetic Biology and featured as an Editor’s Choice in Science Magazine. Synvivia has exclusive license to the...

Sunesis Pharmaceuticals Inc.

Brief Description

Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic...

Artris Therapeutics, Inc.

Brief Description

Artris Therapeutics was founded to identify and develop cancer therapeutics. The company was co-founded by UC Berkeley Professor of Chemical Biology and Molecular Therapeutics Daniel Nomura.

Timeline

2017. Company founded Inventors

Leslie Bateman, Jessica Cestellos Spradlin, Tucker Huffman, David Miyamoto, Elizabeth Anne Moore, Truc Bang Nguyen, Daniel Nomura, James Arthur Olzmann, Allison Marie Roberts, Carl Ward

Juvenon, Inc.

Brief Description

UC Berkeley scientists founded Juvenon to make their healthy aging breakthrough available to the public. The company's patented combination of natural micronutrients promotes a healthier, more energetic body and protects tissue from the toxic oxidants that increase with normal daily stress-producing activities and exercise, as well as with the aging process. Juvenon has expanded to multiple products that enable consumers to maintain vigor and functionality as they age, empowering millions of individuals worldwide to live better longer, and age gracefully.

The...

Singulex, Inc.

Brief Description

Singulex is an immunodiagnostics company at the forefront of Single Molecule Counting technology, a novel immunoassay technology recognized for unprecedented ultra sensitivity in the precision measurement of biomarkers. Singulex is the developer of the Singulex Clarity system, a fully automated, in vitro diagnostics platform powered by Single Molecule Counting technology. With up to 1,000 times more sensitivity than existing technologies, Single Molecule Counting reveals the presence or absence of disease more clearly and definitively than was possible before. The...